Yahoo Finance on Instagram: "Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.⁠ ⁠ "We are encouraged by the weight loss profile of CagriSema. This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement Friday.⁠ ⁠ The results came from a trial of nondiabetic adults with obesity. A second late-stage trial for diabetics is underway, with results expected in the first half of 2025.⁠ ⁠ Novo traded down more than 20% Friday morning, its biggest loss since 2002. The CagriSema news boosted competitors, such as Eli Lilly (LLY), whose stock bumped up more than 6%.⁠ ⁠ The results are significantly better than those of Novo's current GLP-1s, Ozempic for diabetes and Wegovy for weight loss, which provide around 15% weight loss. But Novo's management had been bullish on CagriSema, setting the bar at 25%.⁠ ⁠ "This is below the Street’s expectation of 25% and more comparable to the ~21% for Zepbound. It appears the protocol for the CagriSema trial included flexible dosing, and this led to only ~57% of patients reaching the highest dose of the product/contributed to the lower-than-expected avg weight loss," JPMorgan analysts wrote in a note to clients Friday.⁠ ⁠ Read further at the link in our bio."

2,119 likes, 19 comments - yahoofinance on December 20, 2024: "Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.⁠ ⁠ "We are encouraged by the weight loss profile of CagriSema. This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement Friday.⁠ ⁠ The results came from a trial of nondiabetic adults with obesity. A second late-stage trial for diabetics is underway, with results expected in the first half of 2025.⁠ ⁠ Novo traded down more than 20% Friday morning, its biggest loss since 2002. The CagriSema news boosted competitors, such as Eli Lilly (LLY), whose stock bumped up more than 6%.⁠ ⁠ The results are significantly better than those of Novo's current GLP-1s, Ozempic for diabetes and Wegovy for weight loss, which provide around 15% weight loss. But Novo's management had been bullish on CagriSema, setting the bar at 25%.⁠ ⁠ "This is below the Street’s expectation of 25% and more comparable to the ~21% for Zepbound. It appears the protocol for the CagriSema trial included flexible dosing, and this led to only ~57% of patients reaching the highest dose of the product/contributed to the lower-than-expected avg weight loss," JPMorgan analysts wrote in a note to clients Friday.⁠ ⁠ Read further at the link in our bio.".